Standigm Raises US $11.5 Million in Series B Round Funding to Advance Its AI-Powered Drug Pipelines Toward License-Out
Standigm, an AI-powered drug discovery company, has raised $11.5 million in a Series B funding round. The funds will be used to scale the AI technology platforms and advance its drug discovery pipelines for untreatable diseases.
Seoul, Korea, South, March 29, 2019 --(PR.com)-- Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced it has raised $11.5 million in a Series B funding round led by Mirae Asset Venture Investment and Mirae Asset Capital. Standigm will use the funds to scale the AI technology platforms and advance its drug discovery pipelines toward license-out. The new round brings Standigm’s total financing to $15 million.
The round included participation from Kakao Ventures, Atinum Investment, DSC Investment, LB Investment, Wonik Investment Partners, as well as Mirae Asset Venture Investment and Mirae Asset Capital. Kakao Ventures, one of the leading early-stage VCs in Asia, continued to invest in Standigm since its seed round.
“We have been very impressed with the progress Standigm has made over the past years in global drug discovery market,” said Kijun Kim, Vice President in Kakao Ventures. “The feasibility of Standigm AI is already acknowledged among the leading pharmaceutical companies. We’re pleased to continue our support. This will allow standigm to broaden its own pipelines.”
Launching three platforms, Standigm BEST®, Standigm Insight®, and Standigm Expander®, Standigm has provided lead optimization, novel target analysis, and new indication prediction services to pharmaceutical companies including four global leading pharmaceutical companies. Standigm has developed extensive preclinical pipelines in four different disease areas: NASH, Parkinson’s disease, Autism, and Mitochondrial diseases.
Jinhan Kim, CEO and Co-founder in Standigm, said, “We demonstrated in vitro and in vivo data of our repurposing drug candidates. This latest round from top investors and innovators in AI and biotechnology fields represents their confidence in our technology to innovate drug discovery process in the pharmaceutical industry. We will create partnerships with leading healthcare organizations to accelerate this mission and bolster our pipelines.”
About Standigm
Standigm is a drug discovery company that searches therapeutic lead compounds by using advanced artificial intelligence (AI) trained on biomedical big data. We design lead molecules and predict targets and pathways of untreatable diseases and find new indications of existing drugs with the ensemble of 8 different AI models and a comprehensive graphic knowledge database.
Founded in 2015 by experts in artificial intelligence and systems biology at Samsung Advanced Institute of Technology, Standigm has grown into a team of elite researchers, composed of 50% PhDs with multi-disciplinary expertise in chemistry, biology, pharmacology, and high-performance algorithms and data structures.
Our vision is a full-stack pharmaceutical company that could ease the pains of patients all over the world. For more information, please, visit: www.standigm.com
The round included participation from Kakao Ventures, Atinum Investment, DSC Investment, LB Investment, Wonik Investment Partners, as well as Mirae Asset Venture Investment and Mirae Asset Capital. Kakao Ventures, one of the leading early-stage VCs in Asia, continued to invest in Standigm since its seed round.
“We have been very impressed with the progress Standigm has made over the past years in global drug discovery market,” said Kijun Kim, Vice President in Kakao Ventures. “The feasibility of Standigm AI is already acknowledged among the leading pharmaceutical companies. We’re pleased to continue our support. This will allow standigm to broaden its own pipelines.”
Launching three platforms, Standigm BEST®, Standigm Insight®, and Standigm Expander®, Standigm has provided lead optimization, novel target analysis, and new indication prediction services to pharmaceutical companies including four global leading pharmaceutical companies. Standigm has developed extensive preclinical pipelines in four different disease areas: NASH, Parkinson’s disease, Autism, and Mitochondrial diseases.
Jinhan Kim, CEO and Co-founder in Standigm, said, “We demonstrated in vitro and in vivo data of our repurposing drug candidates. This latest round from top investors and innovators in AI and biotechnology fields represents their confidence in our technology to innovate drug discovery process in the pharmaceutical industry. We will create partnerships with leading healthcare organizations to accelerate this mission and bolster our pipelines.”
About Standigm
Standigm is a drug discovery company that searches therapeutic lead compounds by using advanced artificial intelligence (AI) trained on biomedical big data. We design lead molecules and predict targets and pathways of untreatable diseases and find new indications of existing drugs with the ensemble of 8 different AI models and a comprehensive graphic knowledge database.
Founded in 2015 by experts in artificial intelligence and systems biology at Samsung Advanced Institute of Technology, Standigm has grown into a team of elite researchers, composed of 50% PhDs with multi-disciplinary expertise in chemistry, biology, pharmacology, and high-performance algorithms and data structures.
Our vision is a full-stack pharmaceutical company that could ease the pains of patients all over the world. For more information, please, visit: www.standigm.com
Contact
Standigm
Minyoung So
+82-2-501-8118
www.standigm.com
Minyoung So
+82-2-501-8118
www.standigm.com
Contact
Multimedia
Categories